Boston Pharmaceuticals, Inc.

Brian Michael Naiman

Partha S Chowdhury

Melissa Marie Damschroder

Xiaodong Xiao

Ronald Herbst

Reena Varkey

Stacey Drabic

Qun Du

Ping Tsui

Catherine Ettinger

Jodi Karnell

Laura Carter

Melissa Damschroder

Partha Chowdhury

This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.

Antibodies specific for IL-21 and uses thereof

Growing community of inventors

Gaithersburg, MD, United States of America

Brian Michael Naiman